Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Net Income (2016 - 2025)

Historic Net Income for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$102.2 million.

  • Karyopharm Therapeutics' Net Income fell 23116.66% to -$102.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$196.0 million, marking a year-over-year decrease of 15625.34%. This contributed to the annual value of -$196.0 million for FY2025, which is 15625.34% down from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Net Income stood at -$102.2 million, which was down 23116.66% from -$33.1 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Net Income's 5-year high stood at $38.7 million during Q4 2021, with a 5-year trough of -$102.2 million in Q4 2025.
  • Moreover, its 5-year median value for Net Income was -$36.8 million (2022), whereas its average is -$35.3 million.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Net Income skyrocketed by 18909.97% in 2021, and later tumbled by 25657.36% in 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Net Income (Quarter) stood at $38.7 million in 2021, then tumbled by 201.92% to -$39.4 million in 2022, then fell by 6.73% to -$42.1 million in 2023, then rose by 26.67% to -$30.9 million in 2024, then plummeted by 231.17% to -$102.2 million in 2025.
  • Its Net Income stands at -$102.2 million for Q4 2025, versus -$33.1 million for Q3 2025 and -$37.3 million for Q2 2025.